Overview

Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population

Status:
Enrolling by invitation
Trial end date:
2023-01-01
Target enrollment:
0
Participant gender:
All
Summary
The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Lancaster General Hospital
Treatments:
Pharmaceutical Solutions
Tranexamic Acid
Criteria
Inclusion Criteria:

1. Provision of written informed consent

2. Age > or = to 65 years

3. Hip fracture location within the femoral neck, intertrochanteric, and subtrochanteric
regions

4. Indication for one of the following surgical interventions: hemiarthroplasty, total
hip replacement, sliding plate and screw fixation, or intramedullary fixation

Exclusion Criteria:

1. Indication for closed reduction or percutaneous screw

2. Allergy to TXA

3. Cerebrovascular accident/stroke, active coronary disease/myocardial infarction, or
deep vein thrombosis/pulmonary emboli within one (1) month of the fracture

4. Presence of hypercoaguable disorder